Ultralente insulin: Difference between revisions
CSV import |
No edit summary |
||
| Line 33: | Line 33: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 13:23, 18 March 2025
Ultralente insulin is a type of insulin that is used in the treatment of diabetes. It is a long-acting insulin that is typically injected once or twice a day. Ultralente insulin is also known as extended insulin zinc suspension.
Overview[edit]
Ultralente insulin is a type of insulin that is used in the treatment of both Type 1 and Type 2 diabetes. It is a long-acting insulin that is typically injected once or twice a day. The insulin is designed to be slowly released into the body over a period of 18 to 24 hours, helping to control blood sugar levels throughout the day and night.
Mechanism of Action[edit]
Ultralente insulin works by replacing the insulin that is normally produced by the body. It helps move sugar from the blood into other body tissues where it is used for energy. It also stops the liver from producing more sugar.
Side Effects[edit]
Like all medicines, Ultralente insulin can cause side effects, although not everybody gets them. Some common side effects include hypoglycemia (low blood sugar), lipodystrophy (skin changes at the site of injection), and allergic reactions.
Discontinuation[edit]
Ultralente insulin was discontinued by its manufacturer, Eli Lilly and Company, in 2005. The company stated that the decision was based on the availability of newer, more advanced insulin products.
See Also[edit]
References[edit]
<references />


